Edition:
United States

PhaseRx Inc (PZRX.OQ)

PZRX.OQ on NASDAQ Stock Exchange Capital Market

0.49USD
15 Dec 2017
Change (% chg)

$0.12 (+33.53%)
Prev Close
$0.37
Open
$0.38
Day's High
$0.58
Day's Low
$0.36
Volume
782,909
Avg. Vol
173,767
52-wk High
$1.95
52-wk Low
$0.36

Chart for

About

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $5.78
Shares Outstanding(Mil.): 11.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares

* PHASERX RECEIVES DECISION FROM THE NASDAQ HEARINGS PANEL FOR CONTINUED LISTING OF SHARES

Dec 13 2017

Its cash nearly depleted, PhaseRx files for Ch. 11 to press sale

With only enough cash to stay afloat for a few more weeks, PhaseRx Inc, a developer of treatments for liver diseases, filed for Chapter 11 bankruptcy protection on Monday in a bid to sell itself as soon possible.

Dec 12 2017

BRIEF-PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA

* PHASERX RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR PRX-ASL FROM EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-PhaseRx reports Q3 loss per share $0.23

* PhaseRx reports third quarter 2017 financial results and provides corporate update

Nov 09 2017

BRIEF-Phaserx gets delisting notice from NASDAQ

* Says receipt of delisting notice from NASDAQ informing trading in co's stock will be suspended from NASDAQ at opening of business on Nov 1​ Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Phaserx announces corporate restructuring and review of strategic alternatives

* PhaseRx announces corporate restructuring and review of strategic alternatives

Oct 13 2017

BRIEF-PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL

* PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the treatment of Argininosuccinate Lyase Deficiency Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Phaserx reports Q2 loss per share $0.30

* Phaserx reports second quarter 2017 financial results and provides corporate update

Aug 10 2017

BRIEF-PhaseRx files for stock and warrants offering of up to $15 mln

* PhaseRx Inc files for stock and warrants offering of up to $15 million - sec filing Source text: (http://bit.ly/2sBPItI) Further company coverage:

Jun 21 2017

Earnings vs. Estimates